I Hyodo

Summary

Affiliation: National Shikoku Cancer Center
Country: Japan

Publications

  1. ncbi request reprint Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: a nationwide survey in Japan
    Ichinosuke Hyodo
    Department of Medical Oncology, National Shikoku Cancer Center, Ehime, Japan
    Cancer 97:2861-8. 2003
  2. ncbi request reprint Psychological impact of informed consent in hospitalized cancer patients. A sequential study of anxiety and depression using the hospital anxiety and depression scale
    I Hyodo
    Department of Internal Medicine, National Shikoku Cancer Center Hospital, 13 Horinouchi, Matsuyama, Ehime 790 0007, Japan
    Support Care Cancer 7:396-9. 1999
  3. ncbi request reprint A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting
    I Hyodo
    Department of Internal Medicine, National Shikoku Cancer Center, 13 Horinouchi, 790 0007, Matsuyama, Japan
    Eur J Cancer 39:2328-33. 2003
  4. ncbi request reprint Nationwide survey on complementary and alternative medicine in cancer patients in Japan
    Ichinosuke Hyodo
    Medical Oncology Division, National Shikoku Cancer Center, Horinouchi 13, Matsuyama, 790 0007 Ehime, Japan
    J Clin Oncol 23:2645-54. 2005
  5. pmc Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
    W Koizumi
    Department of Internal Medicine, Kitasato University School of Medicine, 2 1 1 Asamizodai, Sagamihara shi, Kanagawa, Japan
    Ann Oncol 21:766-71. 2010
  6. ncbi request reprint Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection
    J Nasu
    Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
    Endoscopy 37:990-3. 2005
  7. ncbi request reprint Current status of cancer patients' perception of alternative medicine in Japan. A preliminary cross-sectional survey
    K Eguchi
    Department of Medical Oncology, National Shikoku Cancer Center, Ehime Prefecture, Japan
    Support Care Cancer 8:28-32. 2000
  8. ncbi request reprint Serum soluble Fas antigen in gastric MALT (mucosa-associated lymphoid tissue) lymphoma patients
    T Doi
    Dept of Internal Medicine, National Shikoku Cancer Center Hospital, Matsuyama, Japan
    J Exp Clin Cancer Res 18:343-5. 1999
  9. ncbi request reprint Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers
    Junichirou Nasu
    Department of Internal Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
    J Clin Gastroenterol 40:412-5. 2006
  10. ncbi request reprint The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine
    Tomohiro Nishina
    Department of Medical Oncology, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama, Ehime 790 0007, Japan
    Eur J Cancer 40:1566-71. 2004

Collaborators

Detail Information

Publications49

  1. ncbi request reprint Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: a nationwide survey in Japan
    Ichinosuke Hyodo
    Department of Medical Oncology, National Shikoku Cancer Center, Ehime, Japan
    Cancer 97:2861-8. 2003
    ..The authors performed a cross-sectional survey to evaluate the perceptions and attitudes of Japanese clinical oncologists toward cancer CAM...
  2. ncbi request reprint Psychological impact of informed consent in hospitalized cancer patients. A sequential study of anxiety and depression using the hospital anxiety and depression scale
    I Hyodo
    Department of Internal Medicine, National Shikoku Cancer Center Hospital, 13 Horinouchi, Matsuyama, Ehime 790 0007, Japan
    Support Care Cancer 7:396-9. 1999
    ..Physicians should be aware of these facts and pay special attention to their patients' psychological distress in routine clinical practice...
  3. ncbi request reprint A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting
    I Hyodo
    Department of Internal Medicine, National Shikoku Cancer Center, 13 Horinouchi, 790 0007, Matsuyama, Japan
    Eur J Cancer 39:2328-33. 2003
    ..Oral S-1 with weekly cisplatin is a feasible and promising combination regimen that is appropriate for an outpatient setting. A randomised phase II study comparing this combination with S-1 alone in chemo-nai;ve patients is warranted...
  4. ncbi request reprint Nationwide survey on complementary and alternative medicine in cancer patients in Japan
    Ichinosuke Hyodo
    Medical Oncology Division, National Shikoku Cancer Center, Horinouchi 13, Matsuyama, 790 0007 Ehime, Japan
    J Clin Oncol 23:2645-54. 2005
    ..To determine the prevalence of use of complementary and alternative medicine (CAM) by patients with cancer in Japan, and to compare the characteristics of CAM users and CAM nonusers...
  5. pmc Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
    W Koizumi
    Department of Internal Medicine, Kitasato University School of Medicine, 2 1 1 Asamizodai, Sagamihara shi, Kanagawa, Japan
    Ann Oncol 21:766-71. 2010
    ..This study aimed to evaluate the safety and efficacy of S-1 combined with oral leucovorin (LV) to enhance antitumor activity in chemotherapy-naive patients with mCRC...
  6. ncbi request reprint Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection
    J Nasu
    Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
    Endoscopy 37:990-3. 2005
    ..The incidence and characteristics of metachronous multiple gastric cancers were investigated in a retrospective study in patients with early gastric cancer after EMR treatment...
  7. ncbi request reprint Current status of cancer patients' perception of alternative medicine in Japan. A preliminary cross-sectional survey
    K Eguchi
    Department of Medical Oncology, National Shikoku Cancer Center, Ehime Prefecture, Japan
    Support Care Cancer 8:28-32. 2000
    ..Issues that we have to solve are concerned with the education of cancer patients, lay people and physicians on the meaning and role of alternative medicine and on the necessity for scientific evaluation of medical treatments in Japan...
  8. ncbi request reprint Serum soluble Fas antigen in gastric MALT (mucosa-associated lymphoid tissue) lymphoma patients
    T Doi
    Dept of Internal Medicine, National Shikoku Cancer Center Hospital, Matsuyama, Japan
    J Exp Clin Cancer Res 18:343-5. 1999
    ....
  9. ncbi request reprint Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers
    Junichirou Nasu
    Department of Internal Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
    J Clin Gastroenterol 40:412-5. 2006
    ....
  10. ncbi request reprint The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine
    Tomohiro Nishina
    Department of Medical Oncology, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama, Ehime 790 0007, Japan
    Eur J Cancer 40:1566-71. 2004
    ..183 days, P = 0.047). The efficacy of 5'-DFUR could be optimised by preselecting patients with high TP/ DPD ratios in their tumour tissues, and this would be applicable to the treatment with capecitabine...
  11. ncbi request reprint Routine endoscopy using a magnifying endoscope for gastric cancer diagnosis
    H Tajiri
    Department of Internal Medicine, National Shikoku Cancer Center, Ehime, Japan
    Endoscopy 34:772-7. 2002
    ..The aim of this prospective study was to clarify the relationship between the fine mucosal patterns of gastric lesions and histological findings, and also to evaluate the usefulness of magnifying endoscopy during routine endoscopy...
  12. ncbi request reprint Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions
    Y Yamada
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 12:1133-7. 2001
    ....
  13. ncbi request reprint Efficacy of clinical pathway for the management of mucosal gastric carcinoma treated with endoscopic submucosal dissection using an insulated-tip diathermic knife
    Shoji Hirasaki
    Department of Internal Medicine, Shikoku Cancer Center, Matsuyama
    Intern Med 43:1120-5. 2004
    ..The purpose of this study was to evaluate the impact of a clinical pathway and standardize the treatment for mucosal gastric carcinoma treated with IT-ESD...
  14. ncbi request reprint A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer
    Toshikazu Moriwaki
    Department of Medical Oncology, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama, Ehime 790 0007, Japan
    Cancer Chemother Pharmacol 56:138-44. 2005
    ....
  15. ncbi request reprint Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Tria
    Takekazu Yamao
    Department of Internal Medicine, Cancer Institute Hospital, Tokyo, Japan
    Jpn J Clin Oncol 34:316-22. 2004
    ..In this study, we evaluated the efficacy and toxicity of sequential MTX and 5FU therapy (MF) in chemotherapy-naive patients with AGC accompanied by malignant ascites in a phase II setting...
  16. ncbi request reprint Gastric cancer concomitant with inflammatory fibroid polyp treated with endoscopic mucosal resection using an insulation-tip diathermic knife
    Shoji Hirasaki
    Department of Internal Medicine, National Shikoku Cancer Center, 13 Horino uchi, Matsuyama 790 0007
    Intern Med 42:259-62. 2003
    ..Adenocarcinoma in the IIc area was present adjacent to the IFP. This may be the first report of gastric cancer concomitant with gastric IFP treated by endoscopic mucosal resection...
  17. ncbi request reprint Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure
    Ken Hirao
    Department of Internal Medicine, National Shikoku Cancer Center, 13 Horino uchi, Matsuyama 790 0007
    Intern Med 43:106-10. 2004
    ..Second line chemotherapy may have contributed to the favorable clinical outcome in this patient...
  18. ncbi request reprint [Malignant lymphoma with submucosal invasion in the terminal ileum diagnosed with colonoscopy and examined by endoscopic ultrasonography]
    Shoji Hirasaki
    Department of Internal Medicine, National Shikoku Cancer Center
    Nihon Shokakibyo Gakkai Zasshi 101:41-6. 2004
  19. ncbi request reprint Extragonadal retroperitoneal embryonal carcinoma successfully treated with chemotherapy
    Shoji Hirasaki
    Department of Internal Medicine, National Shikoku Cancer Center, 13 Horino uchi, Matsuyama 790 0007
    Intern Med 42:1122-6. 2003
    ..A curative surgical operation revealed that there were no malignant cells in the lung lesions and primary lesion. This patient responded well to chemotherapy and achieved complete remission by chemotherapy...
  20. ncbi request reprint [Psychological support of cancer patients and their relatives following informed consent]
    Ichinosuke Hyodo
    Department of Internal Medicine, National Shikoku Cancer Center
    Nihon Rinsho 61:557-9. 2003
  21. ncbi request reprint Unusual metastasis of hepatocellular carcinoma to the esophagus
    Eiji Tsubouchi
    Department of Internal Medicine, Shikoku Cancer Center, Matsuyama, Japan
    Intern Med 44:444-7. 2005
    ..There were no symptoms due to esophageal tumor. He died of progressive hepatic failure. Cases of premortem-diagnosed esophageal metastasis from HCC are extremely rare...
  22. ncbi request reprint A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer
    Ichinosuke Hyodo
    Division of Gastroenterology, University of Tsukuba, Tsukuba, Ibaraki 305 8575, Japan
    Jpn J Clin Oncol 36:410-7. 2006
    ..Therefore, we performed a phase II study to investigate the 3-week regimen of capecitabine in Japanese patients with metastatic colorectal cancer (MCRC)...
  23. ncbi request reprint Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin
    Fumio Nagashima
    Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
    Jpn J Clin Oncol 35:714-9. 2005
    ..Here, we investigated if these biological markers can predict chemoresponse and survival of unresectable gastric cancer patients treated with irinotecan and cisplatin...
  24. ncbi request reprint Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer
    Junichi Sakamoto
    Department of Epidemiological and Clinical Research Information Management, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Anticancer Drugs 17:231-6. 2006
    ..We conclude that this 4-week regimen of capecitabine showed promising activity and was well tolerated as first-line therapy for advanced/metastatic gastric cancer. Further investigation of this regimen is warranted...
  25. ncbi request reprint Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin
    Narikazu Boku
    Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto gun, Shizuoka, Japan
    Jpn J Clin Oncol 37:275-81. 2007
    ..The purpose of this study is to confirm our previous results and to compare the significance of those markers between continuous infusion of 5-FU (5-FUci) and FP...
  26. ncbi request reprint Timing of significant adverse events is essential information during early development of new drugs
    Ichinosuke Hyodo
    Int J Clin Oncol 11:69; author reply 69-70. 2006
  27. ncbi request reprint [Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer]
    Toshikazu Moriwaki
    Dept of Internal Medicine, National Shikoku Cancer Center
    Gan To Kagaku Ryoho 30:489-94. 2003
    ..These results were similar to those reported in the phase II study for the new drug approval. This study demonstrated the reproducible activity and safety of TS-1 in practice...
  28. ncbi request reprint Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study
    Yashushi Mitachi
    Department of Gastroenterology and Medical Oncology, Sendai Kosei Hospital, 4 15, Hirosecho, Aobaku, Sendai, Miyagi 980 0873, Japan
    Gastric Cancer 5:160-7. 2002
    ....
  29. ncbi request reprint Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study
    Motoki Yoshida
    Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Jpn J Clin Oncol 34:654-9. 2004
    ..The aim of this analysis was to investigate prognostic factors for patients with metastatic gastric cancer treated by chemotherapy, and to identify the characteristics of long-term survivors...
  30. ncbi request reprint How should oncologists face complementary and alternative medicine?
    Ichinosuke Hyodo
    Jpn J Clin Oncol 38:511. 2008
  31. ncbi request reprint Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)
    Atsushi Ohtsu
    Division of Gastrointestinal Oncology Digestive Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    J Clin Oncol 21:54-9. 2003
    ..To compare fluorouracil (FU) alone with FU plus cisplatin (FP) and with uracil and tegafur plus mitomycin (UFTM) for patients with advanced gastric cancer in a prospective, randomized, controlled trial...
  32. doi request reprint Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase
    Wasaburo Koizumi
    Department of Gastroenterology, East Hospital, Kitasato University School of Medicine, Sagamihara City, Kanagawa, Japan
    Anticancer Drugs 19:819-24. 2008
    ..028) in patients with TP-positive and DPD-negative tumors (RR=60%, 6/10) than in the remaining patients (RR=13%, 2/15). TP and DPD expression profiles are useful for predicting a response to capecitabine...
  33. doi request reprint A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial
    Tetsuya Hamaguchi
    Division of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 38:432-7. 2008
    ..Therefore, we conducted a phase II study to evaluate the efficacy and toxicity of sequential treatment with methotrexate (MTX) and also 5-FU as second-line chemotherapy in patients with advanced gastric cancer...
  34. ncbi request reprint [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer]
    Ichinosuke Hyodo
    Division of Gastroenterology, University of Tsukuba, Japan
    Gan To Kagaku Ryoho 33:64-7. 2006
    ..The median survival was 11 months, despite including 11 pre-treated patients. S-1 given with weekly cisplatin was a feasible and promising combination regimen for an outpatient setting...
  35. doi request reprint Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer
    Hiromi Sakamoto
    Nat Genet 40:730-40. 2008
    ..90, 95% CI = 1.56-2.33, P = 8.01 x 10(-11)). The polymorphism of the PSCA gene, which is possibly involved in regulating gastric epithelial-cell proliferation, influences susceptibility to diffuse-type gastric cancer...
  36. ncbi request reprint Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue
    Ichinosuke Hyodo
    J Gastroenterol 41:504-6. 2006
  37. ncbi request reprint [A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer]
    Mitsukuni Suenaga
    Cancer Institute Hospital, Japanese Foundation for Cancer Research
    Gan To Kagaku Ryoho 35:255-60. 2008
    ..There were no treatment-related deaths. Neuro-sensory toxicity was a highly-frequent adverse event (78.9%), but no grade 3/4 neurotoxicity was seen. The FOLFOX4 regimen was acceptable to Japanese patients with ACRC in at least 3 cycles...
  38. ncbi request reprint Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70
    Akinori Yanaka
    Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
    Digestion 75:148-55. 2007
    ..This study was conducted to determine whether a clinical dose of GGA protects the human gastric mucosa from diclofenac (DIC)-induced gastric mucosal injury...
  39. ncbi request reprint [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]
    Toshikazu Moriwaki
    Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center
    Gan To Kagaku Ryoho 34:2249-53. 2007
    ..Non-hematological toxicities were mild. The median survival time was 11 months. The 1-year survival rate was 34%. This study showed the activity and safety of FOLFIRI in practice...
  40. ncbi request reprint [Standard chemotherapy for colonic neoplasms]
    Ichinosuke Hyodo
    Nihon Naika Gakkai Zasshi 96:283-8. 2007
  41. ncbi request reprint Artificial hydration therapy, laboratory findings, and fluid balance in terminally ill patients with abdominal malignancies
    Tatsuya Morita
    Department of Palliative and Supportive Care, Palliative Care Team and Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Japan
    J Pain Symptom Manage 31:130-9. 2006
    ..Calculated fluid balance is not an appropriate alternative to direct monitoring of patient symptoms. More studies are needed to determine the clinical efficacy of artificial hydration for terminally ill cancer patients...
  42. ncbi request reprint Incidence and underlying etiologies of bronchial secretion in terminally ill cancer patients: a multicenter, prospective, observational study
    Tatsuya Morita
    Seirei Hospice, Seirei Mikatabara Hospital, Hamamatsu, Shizuoka, Japan
    J Pain Symptom Manage 27:533-9. 2004
    ..Etiology-based classification of bronchial secretion is useful to identify the most suitable palliative treatments and to clarify treatment efficacy in each specific pathophysiology...
  43. ncbi request reprint Seronegative alpha-fetoprotein-producing early gastric cancer treated with endoscopic mucosal resection and additional surgery
    Shoji Hirasaki
    Department of Internal Medicine, Shikoku Cancer Center, 13 Horino uchi, Matsuyama 790 0007
    Intern Med 43:926-30. 2004
    ..This patient remains alive without disease for 3 years after surgery...
  44. ncbi request reprint [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient]
    Yasuo Shima
    Palliative Care Unit, National Cancer Center Hospital East
    Gan To Kagaku Ryoho 31:1377-82. 2004
    ..4%) showed an excess of liver enzymes but no clinically suspected adverse effect was observed. Octreotide is effective and well tolerated in terminally ill cancer patients with malignant bowel obstruction...
  45. ncbi request reprint [Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer]
    Toshikazu Moriwaki
    Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center
    Gan To Kagaku Ryoho 31:1373-6. 2004
    ..Non-hematological toxicities were mild. The median survival time was 4.8 months. One-year survival rate was 15%. This study showed the reproducible activity and safety of GEM in practice...
  46. ncbi request reprint [Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer]
    Tomohiro Nishina
    Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center
    Gan To Kagaku Ryoho 31:1361-4. 2004
    ..This retrospective study demonstrated the reproducible activity and safety of CPT-11 for the treatment of fluoropyrimidine-resistant advanced colorectal cancer in clinical practice...
  47. ncbi request reprint Multiple synchronous early gastric carcinoma with seven lesions
    Shoji Hirasaki
    J Gastroenterol 38:1194. 2003
  48. ncbi request reprint Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer
    Yasuhide Yamada
    Division of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 52:125-30. 2003
    ..We evaluated the antitumor activity and toxicity of a combination of irinotecan and MMC in patients with metastatic colorectal cancer resistant to fluoropyrimidines...
  49. ncbi request reprint A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703)
    Atsushi Ohtsu
    Division of Gastrointestinal Oncology Digestive Endoscopy, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Japan
    Jpn J Clin Oncol 33:28-32. 2003
    ....